Drugs / pulocimab
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04547205 | Jun 2020 → Mar 2021 | cancer | Akeso | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05142423 | Nov 2021 → Apr 2027 expected | — | Akeso | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04982276 | Aug 2021 → Dec 2025 overdue | gastroesophageal adenocarcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06341335 | Jun 2024 → Nov 2026 expected | adenocarcinoma | Akeso | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pulocimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06341335 ↗ |
| Known as | AK109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04547205 ↗ |
| Modality | Monoclonal antibody | “novel anti-VEGFR2 monoclonal antibody” PMID 36989884 ↗ Mar 2023 |
| Route | Intravenous | “AK109, 2#4#8#12#18mg/kg, IV, every 2 weeks (Q2W), or 15 mg/kg every 3 weeks(Q3W)” NCT04547205 ↗ |